دورية أكاديمية
أعرض في EDS

Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells.

التفاصيل البيبلوغرافية
العنوان: Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells.
المؤلفون: Deola S; San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Scientific Institute HS Raffaele, Milan, Italy. deola.sara@hsr.it, Scaramuzza S, Birolo RS, Cergnul M, Ficara F, Dando J, Voena C, Vai S, Monari M, Pogliani E, Corneo G, Peccatori J, Selleri S, Bordignon C, Roncarolo MG, Aiuti A, Bregni M
المصدر: Journal of translational medicine [J Transl Med] 2007 Jul 12; Vol. 5, pp. 35. Date of Electronic Publication: 2007 Jul 12.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, 2003-
مواضيع طبية MeSH: Hematopoietic Stem Cell Mobilization* , Transduction, Genetic*, Antigens, CD34/*metabolism , Blood Component Removal/*methods , Cell Culture Techniques/*methods , Multiple Myeloma/*pathology , Retroviridae/*genetics, Cell Division ; Humans ; Plasma Cells/pathology ; Tumor Burden
مستخلص: Background: Tumor cell contamination of the apheresis in multiple myeloma is likely to affect disease-free and overall survival after autografting.
Objective: To purge myeloma aphereses from tumor contaminants with a novel culture-based purging method.
Methods: We cultured myeloma-positive CD34+ PB samples in conditions that retained multipotency of hematopoietic stem cells, but were unfavourable to survival of plasma cells. Moreover, we exploited the resistance of myeloma plasma cells to retroviral transduction by targeting the hematopoietic CD34+ cell population with a retroviral vector carrying a selectable marker (the truncated form of the human receptor for nerve growth factor, DeltaNGFR). We performed therefore a further myeloma purging step by selecting the transduced cells at the end of the culture.
Results: Overall recovery of CD34+ cells after culture was 128.5%; DeltaNGFR transduction rate was 28.8% for CD34+ cells and 0% for CD138-selected primary myeloma cells, respectively. Recovery of CD34+ cells after DeltaNGFR selection was 22.3%. By patient-specific Ig-gene rearrangements, we assessed a decrease of 0.7-1.4 logs in tumor load after the CD34+ cell selection, and up to 2.3 logs after culture and DeltaNGFR selection.
Conclusion: We conclude that ex-vivo culture and retroviral-mediated transduction of myeloma leukaphereses provide an efficient tumor cell purging.
References: Blood. 2000 Apr 1;95(7):2234-9. (PMID: 10733490)
Nature. 2006 Sep 21;443(7109):E5-6; discussion E6-7. (PMID: 16988659)
J Gene Med. 2001 May-Jun;3(3):219-27. (PMID: 11437327)
J Clin Oncol. 2001 Sep 1;19(17):3771-9. (PMID: 11533101)
Exp Hematol. 2002 Jan;30(1):82-8. (PMID: 11823041)
Br J Haematol. 2002 Jan;116(1):202-10. (PMID: 11841418)
Exp Hematol. 2002 Jul;30(7):824-30. (PMID: 12135682)
Nat Med. 2003 Apr;9(4):367-9. (PMID: 12669036)
Lancet Oncol. 2003 May;4(5):293-304. (PMID: 12732167)
N Engl J Med. 2003 May 8;348(19):1875-83. (PMID: 12736280)
Science. 2003 Oct 17;302(5644):415-9. (PMID: 14564000)
Hum Gene Ther. 2003 Dec 10;14(18):1727-39. (PMID: 14670124)
N Engl J Med. 2003 Dec 25;349(26):2495-502. (PMID: 14695409)
Hum Gene Ther. 2004 Mar;15(3):305-11. (PMID: 15018739)
J Immunol. 1981 Apr;126(4):1614-9. (PMID: 7009746)
Lancet. 1993 Jan 9;341(8837):85-6. (PMID: 8093407)
Lancet. 1993 Nov 6;342(8880):1134-7. (PMID: 7901474)
Br J Haematol. 1994 Oct;88(2):325-31. (PMID: 7803277)
Blood. 1995 Jul 1;86(1):381-9. (PMID: 7540887)
Blood. 1995 Jul 1;86(1):390-7. (PMID: 7540888)
Hum Gene Ther. 1995 Jun;6(6):813-9. (PMID: 7548281)
Blood. 1996 Feb 15;87(4):1625-34. (PMID: 8608257)
Blood. 1996 Oct 15;88(8):3166-75. (PMID: 8874217)
Br J Haematol. 1997 Feb;96(2):403-11. (PMID: 9029033)
Bone Marrow Transplant. 1997 Feb;19(4):337-42. (PMID: 9051243)
Cancer Gene Ther. 1997 May-Jun;4(3):148-56. (PMID: 9171933)
Science. 1997 Jun 13;276(5319):1719-24. (PMID: 9180086)
Leukemia. 1997 Oct;11(10):1793-8. (PMID: 9324303)
Blood. 1998 Jun 15;91(12):4489-95. (PMID: 9616143)
Blood. 1998 Nov 1;92(9):3131-6. (PMID: 9787148)
J Cancer Res Clin Oncol. 2005 Apr;131(4):214-8. (PMID: 15616828)
Exp Hematol. 2000 Jul;28(7):858-70. (PMID: 10907648)
معلومات مُعتمدة: TGT06S01 Italy TI_ Telethon
فهرسة مساهمة: Note: Original DateCompleted: 20070821
المشرفين على المادة: 0 (Antigens, CD34)
تواريخ الأحداث: Date Created: 20070714 Date Completed: 20091203 Latest Revision: 20220408
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC1948885
DOI: 10.1186/1479-5876-5-35
PMID: 17626627
قاعدة البيانات: MEDLINE
الوصف
تدمد:1479-5876
DOI:10.1186/1479-5876-5-35